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Subjective health status and health-related
quality of life among women with Recurrent
Vulvovaginal Candidosis (RVVC) in Europe and
the USA
Samuel Aballéa1*†, Florent Guelfucci2*†, Julian Wagner3, Amine Khemiri4, Jean-Paul Dietz5, Jack Sobel6
and Mondher Toumi1*
Abstract
Background: Recurrent vulvovaginal candidosis (RVVC) is a chronic condition causing discomfort and pain. Health
status and health-related quality of life (HRQoL) in RVVC were never previously described using validated
questionnaires. The objective of this study is to describe subjective health status and HRQoL and estimate health
state utilities among women with RVVC.
Methods: A cross-sectional online survey was conducted among women who reported having suffered four or
more yeast infections over the past 12 months, in five European countries (France, Germany, Italy, Spain and the
UK) and the USA. Index scores were derived from the EQ-5D, a questionnaire providing a single index value for
health status. The SF-36 questionnaire was used for HRQoL assessment. Information on disease severity, treatment
patterns and productivity was also collected.
Results: 12,834 members of online research panels were contacted. Among them, 620 women with RVVC (5%)
were selected to complete the full questionnaire. The mean EQ-5D index score was 0.70 (95% confidence interval:
[0.67, 0.72]) and the difference between women with a yeast infection at the time of questionnaire completion and
other respondents was 0.05 (p = 0.47). The EQ-5D index score increased significantly with the time since last
infection (p < 0.001). 68% of women reported depression/anxiety problems during acute episode, and 54% outside
episodes, compared to less than 20% in general population (p < 0.001). All SF-36 domain scores were significantly
below general population norms. Mental health domains were the most affected. The impact on productivity was
estimated at 33 lost work hours per year on average, corresponding to estimated costs between €266/year and
€1,130/year depending on the country.
Conclusions: Subjective health status and HRQoL during and in between acute inflammatory episodes in women
with RVVC are significantly worse than in the general population, despite the use of antifungal therapy. The average
index score in women with RVVC is comparable to other diseases such as asthma or COPD and worse than
diseases such as headache/migraine according to US and UK catalogs of index scores. The survey also revealed a
significant loss of productivity associated with RVVC.
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Background
Recurrent vulvovaginal candidosis (RVVC) is a debilitating
chronic infectious condition. It is defined as four or more
acute inflammatory episodes of VulvoVaginal Candidosis
(VVC), also known as vaginal yeast infection, within a year
[1,2]. The prevalence of RVVC is estimated at 6-8% in
women aged between 18 and 65 years in the USA and
Western Europe, according to two large studies [3,4] and
similar estimates can be derived from assessments of
RVVC prevalence as proportion of VVC cases and studies
on population-based VVC prevalence [3-8].
The main symptoms of yeast infections are inflamma-
tion, itching, an abnormal vaginal discharge and painful
sexual intercourse and urination. Such symptoms cause
variable but often severe discomfort and pain. Acute in-
flammatory episodes usually are treated with anti-fungal
drugs of the azole class. They are efficient in clearing the
acute infection, but are unable to prevent recurrences,
which occur on average after a few months only. Guide-
lines from a number of medical associations recommend a
long-term suppressive treatment regimen with an anti-
fungal drug, usually fluconazole, for at least 6 months, off
label [9,10], which can prevent recurrences for the dur-
ation of the therapy, whereas recurrence rates of 60-70%
within 6 months after treatment cessation were reported
[11,12]. A modified weaning scheme over 12–18 months
achieved a lower recurrence rate (36%) within 6 months
after complete treatment cessation [13]. The cost of long-
term treatment has been estimated at AUD 900 ($ 862) in
Australia [14]. Many RVVC patients turn to alternative
remedies like yoghurt and vinegar which only have very
short-term palliative effects [15,16].
Clinical impression is that RVVC patients, despite
current treatment options, suffer from a substantially im-
paired health-related quality of life (HRQoL), but quantifi-
able evidence is scarce. Nyirjesy et al. applied several
validated pain, stress and depression measurements to a
population of physician-diagnosed patients (N = 38) and
observed a proportion of 29% with a clinical depression
[17]. Mendling et al. reported SF-36 scores and further
HRQoL-related information from a longitudinal study on
RVVC patients receiving different therapeutic treatments
(N = 3x30), indicating that mental health was more af-
fected than physical health [18].
To our knowledge, no other study has been conducted to
elicit subjective health status or to assess global HRQoL of
RVVC patients. In times of limited health care budgets, the
availability of quantitative data on the medical need of a de-
bilitating but not life-threatening condition, comparable
across countries and indications, are a prerequisite for
stakeholders and decision makers to engage into research
and development of innovative treatment approaches.
The primary objective of this study was to assess subject-
ive health status and HRQoL, and more specifically to
estimate health state utilities, among women with RVVC,
compared to general female population. Secondary objec-
tives were to describe the impact of the disease on subjective
health status during and in between acute inflammatory epi-
sodes, and to assess productivity and activity impairment.
Methods
Respondent recruitment and selection
A cross-sectional online survey was conducted in five
European countries (France, Germany, Italy, Spain and
UK) and USA using pre-existing market research panels.
A target sample size of 100 respondents with RVVC was
set for each country. Respondents were recruited using
the Research Now family of panels which included
6,000,000 panellists [19]. The panellists received an incen-
tive from €0.5 to €5 for their participation in the survey.
The questionnaire was initially developed and launched
in the UK. It was first tested on 40 persons from the UK
panel (soft launch). The purpose of this pilot phase was to
check whether there was any obvious misunderstanding of
questions or unexpected answers, and that the routing be-
tween questions was correct. Based on findings from the
pilot study, minor corrections were made (described
below), and other panel members from the UK were invited
to participate in the survey until 100 full questionnaires
were completed (full launch). After reviewing the collected
data, the questionnaire was translated and launched in
other countries. Any respondents with a time of completion
lower than 33% of the RVVC sample median completion
time were removed.
The questionnaire started with five screening ques-
tions to identify women with RVVC aged between 18
and 65 years who had been told at least once by a health
care professional that they had a yeast infection, and
who experienced at least four yeast infections over the
past 12 months. Age quotas were used to ensure that
the sample was representative of women with RVVC.
The screening questions were slightly re-worded after
the soft launch in the UK. It was initially asked UK par-
ticipants if they had more than four episodes in the last
12 months, and the exact number of episodes was
established later in the full questionnaire. Nine women
had answered during the screening phase that they had
more than four yeast infections in the last 12 months,
but subsequently gave a number of infections lower than
four in the main part of the questionnaire. We did not
consider those women in our analysis and revised the
questionnaire accordingly. In the final version, women
were asked to state the exact number of episodes in the
screening section, to determine their eligibility for com-
pleting the main questionnaire. The women who were
identified with RVVC in the screening completed the
main questionnaire immediately after answering the
screening questions.
Aballéa et al. Health and Quality of Life Outcomes 2013, 11:169 Page 2 of 13
http://www.hqlo.com/content/11/1/169
The main questionnaire started with two questions to
determine whether the participant had an acute VVC
episode at the time of answering the questionnaire, and
if not, the time elapsed since the last episode.
Health status and HRQoL measurement
As the primary objective was to compare subjective health
status and HRQoL in women with RVVC to general popu-
lation norms, generic instruments were used: the EQ-5D
to elicit health state utilities [20] and the SF-36 to provide
more detailed description of HRQoL [21,22]. EQ-5D is
one of the most widely used preference-based instruments
for the assessment of subjective health status enabling
comparisons with other diseases, and helping payers to
arbitrate on allocation of resources between different
treatments, potentially in different therapeutic areas. This
instrument is recommended by the UK National Institute
for Health and Clinical Excellence (NICE) for eliciting
utilities, i.e. weights used to estimate quality-adjusted life-
years in the context of cost-effectiveness analysis [23]. EQ-
5D is designed for self-completion by respondents and is
suitable for use in postal or online surveys [24].
As it takes only a short time to complete, it was possible
to ask the respondents to answer the EQ-5D twice. Firstly,
respondents described their health state on the day of com-
pleting the questionnaire. Secondly, respondents who indi-
cated having an acute episode on that day were asked to
describe their health state on days without infection; others
were asked to describe their health state on days with in-
fection (Figure 1). Therefore, we were able to compare the
health states during acute episode and between episodes
for each woman in the last 12 months. However, these data
were not used for the UK, because the question about
having an episode at the time of completing the question-
naire appeared to be misunderstood. This question was
rephrased before launching the study for other countries.
The SF-36 (version two) [21], another generic ques-
tionnaire, is more detailed than EQ-5D and frequently
used to describe the disease’s burden in terms of HRQoL
compared to the general population. It consists of 36
items, from which eight domain scores and two sum-
mary measures of health (the Physical Health Compo-
nent Summary, PCS, and the Mental Component
Summary, MCS) can be derived [25]. Validated transla-
tions are available for both EQ-5D and SF-36 for all the
countries included in the study.
Disease characteristics and management
To investigate the relationship between disease charac-
teristics and HRQoL, another part of the questionnaire
aimed to gather information on disease characteristics
(frequency and duration of episodes, duration of disease)
and disease management (history of long-term antifun-
gal therapy, history of referral to a specialist).
Work productivity and activity impairment
Questions on the impact on work and activities were
directly adapted from a validated questionnaire (WPAI)
[26] replacing “During the past seven days …” by
“Thinking back to your most recent yeast infection…”
and “…your health problems…” by “…your last infec-
tion…”. In the absence of validation of the questionnaire
in French, German or Italian, the questions have been
translated by native speakers and validated by experts.
The cost associated with work hours lost due to RVVC
was estimated by country, by multiplying the correspond-
ing number of lost work hours by the average hourly wage.
Average national hourly wages were obtained using aver-
age annual wages in 2011 and average annual hours actu-
ally worked per worker [27] provided by the Organisation
for Economic Co-operation and Development (OECD).
Utility valuation
Utility scores were estimated during acute episodes and
between acute episodes using EQ-5D, and were com-
pared to general population scores from the literature.
Different value sets were available for EQ-5D, based on
preference weights elicited in different countries [20]. In
order to facilitate comparisons and generate an average
score across all countries, preference weights elicited from
the general population of the UK were first applied for all
countries. The UK value set is the most widely used, and
recommended by the EuroQol Group for use in cost-
effectiveness/utility studies and comparative studies and to
facilitate international comparisons [20,28]. These weights
were generated from a large sample of the general
population in the UK using the time-trade off (TTO)
technique [29]. Utilities were also estimated based on
preference weights elicited locally, in France, Germany,
Spain and the USA. This was not possible for Italy
where no set of values was developed.
Statistical analysis
EQ-5D norms for proportions of patients reporting
problems on each of the five EQ5D dimensions were
reported by the EuroQol group [30] for the USA, Spain
and Germany and by König et al. [29] for France and
Italy. EQ-5D utility population norms were available for
the US [31] and the UK [32,33], and calculated using
proportions of patients by level on each dimension and
country specific valuation formulas for other countries.
Utility values in general population were adjusted on the
age distribution of the RVVC sample for Spain, Germany,
US and UK but no age adjustments were made for France
and Italy, as no breakdown by age group was found. How-
ever, König et al. analysed the effect of country on the
occurrence of problems using multiple logistic regressions
and controlling for socio-demographic variables. The
paper presented odds ratio for different age categories. In
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a sensitivity analysis, age-adjusted population norms were
obtained by applying these odds ratios on all dimensions
of the EQ-5D.
Proportions of women reporting problems on each EQ-
5D dimension were compared with population norms
using the chi-square test of independence or Fisher’s exact
test. Linear regression analyses on the EQ-5D utility at
completion of the questionnaire were performed to deter-
mine the drivers of EQ-5D utility among disease-related
variables, adjusting on patient characteristics.
For SF-36, individual scores can be compared with the
population mean by transforming the individual score
into standardized scores (Z-score and T-score) for each
domain and summary component. As SF-36 norms were
not found for most countries, the US population means
and standard deviations were systematically used in the
calculation of the standardized scores. After transform-
ation, the average score in the general population was 50
and the standard deviation is 10. Whenever a domain or
summary score was below 50, this indicated that HRQoL
was worse in the studied population compared to the
general population, and each point was one-tenth of a
standard deviation. The correlation between EQ-5D di-
mensions and the SF-36 scales were calculated using the
Spearman correlation coefficients.
Results
Patients & disease characteristics
12,834 members of online research panels were
contacted and entered the self- screening questions. 865
women did not complete it and 4,389 women were not
included in the study because the target number of re-
spondents in their age group had been reached, not be-
cause they did not fulfil the criteria for RVVC. Of 7,580
(59%) women who completed the screening questions
(excluding women out of the quotas), 639 (8.4%) were
selected to complete the full questionnaire (5% of total
contacted). The full questionnaire was completed by 620
women. Their mean age was 32 years (Table 1).
Thirty women (5.8%) reported suffering a yeast infec-
tion on the day of completing the questionnaire, across
all countries (except UK) and 20.6% had an infection less
RVVC patients currently having the disease (≥4 acute episodes during past 12 months)
n=620
RVVC patients having acute episode on day of
questionnaire completion 
(FR, IT, SP,GER, US) 
n=30 
RVVC patients between acute episodes on day
of questionnaire completion
 (FR, IT, SP, GER, US)
n=490 
EQ-5D asked for
day of quest. 
completion
(acute episode)
n= 30
Utility = 0.64  
EQ-5D asked for
other days
(between episodes)
n=30
Utility = 0.84  
EQ-5D asked for
other days
(acute episode) 
n=490
Utility  = 0.50
RVVC patients on day of
questionnaire completion
 in UK
n=100 
EQ-5D asked for day of 
quest. Completion
n=100
Utility = 0.74
EQ-5D acute episodes
N=520
Utility = 0.51 
EQ-5D between episodes
N=520
Utility  = 0.70 
EQ-5D asked for day
of quest. 
Completion, 
(between episodes)
n=490
Utility = 0.69  
RVVC patients on the day of questionnaire completion
n=620
Utility = 0.70 
Figure 1 Mean EQ-5D utilities (based on UK TTO tariff) by patient subgroup, according to presence of symptoms on the day of
questionnaire completion.
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Table 1 Patient characteristics
UK France Spain Italy Germany USA Total
N 100 107 100 105 106 102 620
Age Mean 30.3 (9.6) 32.3 (10.8) 32.1 (10.6) 32.1 (10.6) 31.4 (10.8) 32.1(10.8) 31.8 (10.5)
Median (range) 27.0 [18.0; 56.0] 29.0 [18.0; 61.0] 29.0 [18.0; 60.0] 28.0 [19.0; 60.0] 28.0 [18.0; 62.0] 29.0 [18.0;63.0] 28.0 [18.0; 63.0]
Marital status Single 37 (37.0%) 23 (21.50%) 23 (21.7%) 48 (45.7%) 37 (35.6%) 30 (29.4%) 195 (31.5%)
Married 22 (22.0%) 33 (30.84%) 35 (33.0%) 32 (30.5%) 32 (30.8%) 50 (49.0%) 204 (32.9%)
Divorced 2 (2.0%) 7 (6.54%) 3 (2.8%) 5 (4.8%) 1 (1.0%) 6 (5.9%) 23 (3.7%)
Separated 1 (1.0%) 0 2 (1.9%) 0 4 (3.9%) 3 (2.9%) 10 (1.6%)
Living with partner 38 (38.0%) 44 (41.1%) 43 (40.6%) 20 (19.1%) 30 (28.9%) 13 (12.8%) 188 (30.3%)
Number of employed women N (%) 71 (71.0%) 83 (77.5%) 62 (62.0%) 60 (57.1%) 78 (73.5%) 69 (67.7%) 423 (68.2%)
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than a week ago. The mean duration of an acute episode
was relatively homogeneous between countries, varying
from 6.5 days to 7.4 days, apart from Spain (10.8 days).
The average number of infections in the last 12 months
was between five and six (Table 2). Overall, the periods
with infection added up to 5.8 weeks on average over
12 months.
48% of the RVVC women (N = 299) had been treated
with a long-term antifungal treatment at least once
(Table 2). Among them, 141 were treated at the time
they answered the questionnaire, and 158 were treated
previously. Among the 158 women previously treated
with long-term antifungal, 121 (77%) completed the nor-
mal course of the treatment and 92 (61%) had at least
one relapse since stopping long-term antifungal treat-
ment. 75% of the women reported they had seen a
gynaecologist.
Impact of RVVC on subjective health status and HRQoL
The proportion of women with problems related to
pain/discomfort of EQ-5D was 63% on average (from
55% in Germany to 78% in Italy) whereas the propor-
tions in the general population did not exceed 35%
(from 23% in Spain to 35% in France). Anxiety/depres-
sion was also significantly affected, with 53% of women
reporting some or severe problems on that dimension
(from 43% in UK to 62% in Italy), compared to below
20% in the general population. Substantial differences
between our sample and the general population were
also found for problems related to usual activities. Dif-
ferences vs. the general population were significant for
all dimensions (see Table 3).
The average utility score for women with RVVC across
six countries was estimated at 0.70 on the day of com-
pletion of the questionnaire (Table 4). The utilities
obtained using the country-specific preference weights
were significantly lower than the age-adjusted general
population, with a difference vs. general population
norms ranging from 0.08 in Germany to 0.21 in Spain
(Table 4).
All SF-36 domain scores, presented in the Figure 2,
were significantly lower among women with RVVC than
Table 2 Disease characteristics & treatment
UK* France Spain Italy Germany USA Total
Last time the women
experienced the symptoms
N 107 100 105 106 102 520
Today N (%) 5 (4.7%) 4 (4.0%) 7 (6.7%) 7 (6.6%) 7 (6.9%) 30 (5.8%)
Less than a week ago N (%) 27 (25.2%) 18 (18.0%) 20 (19.1%) 20 (18.9%) 22 (21.6%) 107 (20.6%)
1 to 4 weeks ago N (%) 42 (39.3%) 49 (49.0%) 55 (52.4%) 42 (39.6%) 47 (46.1%) 235 (45.2%)
1 to 3 months ago N (%) 24 (22.4%) 24 (24.0%) 15 (14.3%) 23 (21.7%) 24 (23.5%) 110 (21.2%)
3 to 6 months ago N (%) 6 (5.6%) 4 (4.0%) 5 (4.8%) 10 (9.4%) 2 (2.0%) 27 (5.2%)
More than 6 months ago N (%) 3 (2.8%) 1 (1.0%) 3 (2.9%) 4 (3.8%) 0 11 (2.1%)
Symptoms today: n (%) N 5 4 7 7 7 30
Vaginal itching and/or Burning N (%) 5 (100.0%) 4 (100.0%) 7 (100.0%) 6 (85.7%) 4 (57.1%) 26 (86.7%)
Thick, white or yellowish
vaginal discharge
N (%) 4 (80.0%) 4 (100.0%) 6 (85.7%) 4 (57.1%) 5 (71.4%) 23 (76.7%)
Pain on intercourse N (%) 2 (40.0%) 3 (75.0%) 2 (28.6%) 1 (14.3%) 3 (42.9%) 11 (36.7%)
Pain and burning on urination N (%) 0 1 (25.0%) 4 (57.1%) 3 (42.9%) 4 (57.1%) 12 (40.0%)
Number of infections
N 100 107 100 105 106 102 620
Mean (SD) 5.74 (2.19) 5.22 (1.43) 5.22 (1.45) 5.28 (1.54) 5.05 (1.26) 5.60 (1.81) 5.34 (1.64)
Duration of infection (days)
N 100 107 100 105 106 102 620
Mean (SD) 6.96 (5.00) 7.01 (4.31) 10.75 (12.25) 7.43 (4.94) 6.50 (4.76) 6.66 (4.65) 7.57 (6.77)
Patients treatment with
long-term antifungal therapy
N 100 107 100 105 106 102 620
Patients never treated N (%) 68 (68.00%) 45 (42.06%) 45 (42.45%) 29 (27.62%) 72 (69.23%) 64 (62.75%) 321 (51.8%)
Patients currently treated N (%) 12 (12.00%) 29 (27.10%) 25 (23.81%) 42 (40.38%) 9 (8.49%) 26 (25.49%) 141 (22.7%)
Previously treated N (%) 20 (20.00%) 33 (30.84%) 36 (33.96%) 34 (32.38%) 23 (22.11%) 12 (15.79%) 158 (25.5%)
*Data about symptoms not available for the UK, as questions about symptoms were formulated differently in the UK version.
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in the general population. Results were homogeneous
across countries with T-scores varying from 34 to 37 for
mental health scores and from 45 to 46 for the pain
scores. The most significantly affected domains were
those related to mental health, particularly the “emo-
tional well-being” and “role limitation emotional” do-
mains. The average mental component summary score
was estimated at 34.72 (95% CI: [33.74; 35.71]).
Health state utility values during and outside infection
periods
Analyses comparing health state utilities during and out-
side infection periods were conducted for all countries ex-
cept the UK (Figure 1 and Table 4). The average utility
during the last infection, whenever it occurred (during the
completion of questionnaire or before), was lower than
the utility outside infection (0.51 vs. 0.70; Table 4). 90.8%
of women had pain/discomfort problems during the last
episode, vs. 60.8% outside infections, (p < 0.0001), on aver-
age across five countries. Differences were smaller on the
anxiety/depression dimension, as many women reported
suffering anxiety or depression between acute episodes.
The difference was smaller when separating women
with or without infection at the time of completing the
questionnaire: the utility score was estimated at 0.69
without infection vs. 0.64 with infection (p < 0.001).
The regression model in Table 5 shows that respondents
with a longer time since last symptoms had a higher utility
on the day of questionnaire completion. For example, the
difference in utility between women without symptoms
for three months and those with symptoms in the past
week was 0.1633 (p = 0.0033), all other things equal. In
addition, women undergoing long-term antifungal therapy
had a significantly lower utility compared to those treated
in the past or never treated. The effect of the time since
the disease onset was tested but this variable was not in-
cluded in the final model as it did not impact significantly
the EQ-5D utility.
The health status of women with RVVC was not only
lower than the general population during an acute episode,
Table 3 Proportions by EQ-5D dimensions and correlation with SF-36
Number of
women
EQ-5D
mobility
EQ-5D
self-care
EQ-5D usual
activities
EQ-5D pain/
discomfort
EQ-5D anxiety/
depression
Source
Proportions of patients with problems at the completion day
UK RVVC sample N = 100 17.0% 8.0% 24.0% 60.0% 43.0%
General population N = 1926 13.4% 3.1% 11.9% 25.4% 18.4% euroqol
Test (p-value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
France RVVC sample N = 107 12.2% 5.6% 17.8% 65.4% 57.0%
General population N = 2,892 13.2% 4.1% 10.0% 35.3% 14.6% Konig et al.
General pop (adjusted) N = 2,892 17.1% 5.4% 13.5% 49.0% 21.8%
Test (p-value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Spain RVVC sample N = 100 20.0% 20.0% 29.0% 60.0% 49.0%
General population N = 323 5.9% 0.4% 5.5% 22.9% 18.1% euroqol
Test (p-value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Italy RVVC sample N = 105 35.2% 22.9% 56.2% 78.1% 61.9%
General population N = 4,709 12.0% 4.3% 10.9% 27.6% 9.3% Konig et al.
General pop (adjusted) N = 4,709 15.6% 5.7% 14.7% 38.3% 13.9%
Test (p-value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Germany RVVC sample N = 106 17.0% 5.7% 25.5% 54.7% 50.9%
General population N = 340 7.4% 1.1% 6.7% 27.4% 19.6% euroqol
Test (p-value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
USA RVVC sample N = 102 29.4% 20.6% 33.3% 57.8% 55.9%
Total RVVC sample N = 620 17.0% 5.7% 25.5% 54.7% 50.9%
Spearman correlation coefficients with:
Physical health - SF36 Correlation coeff. −0.41027 −0.37495 −0.41759 −0.39627 −0.21067
P-value <.0001 <.0001 <.0001 <.0001 <.0001
Mental health - SF36 Correlation coeff. −0.2122 −0.18161 −0.20143 −0.22917 −0.44891
P-value <.0001 0.0002 <.0001 <.0001 <.0001
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but also outside infections. Large differences in the propor-
tions of subjects reporting problems were found for the
anxiety/depression dimension, between women with RVVC
during infection-free periods (54%) and women in general
(≤20%). The difference was largest in Italy, where 60%
reported anxiety/depression problems outside episodes vs.
9.3% in the general population (Figure 3).
Work productivity and activity impairment
Around 50% of the RVVC sample claimed the disease
impacted their daily normal activity (from 45% for UK
to 60% for USA). In addition, working women with
RVVC missed around six hours of work per episode of
yeast infection (Table 6). Therefore, the individual num-
ber of missing hours (hours per episode * episodes per
Table 4 EQ-5D utilities
UK France Spain Italy Germany USA Total
All RVVC sample, during the day of completion of the questionnaire (a)
N 100 107 100 105 106 102 620
(UK TTO formula) Mean (Sd) 0.74 (0.28) 0.72 (0.25) 0.67 (0.34) 0.61 (0.30) 0.76 (0.25) 0.68 (0.34) 0.70 (0.30)
(country specific formula) Mean (Sd) 0.74 (0.28) 0.77 (0.23) 0.72 (0.32) - 0.86 (0.20) 0.76 (0.23) -
Women with infection, during the day of completion of the questionnaire
N 5 4 7 7 7 30
(UK TTO formula) Mean (Sd) - 0.62 (0.41) 0.48 (0.30) 0.73 (0.10) 0.79 (0.34) 0.53 (0.33) 0.64 (0.31)
(country specific formula) Mean (Sd) - 0.78 (0.22) 0.73 (0.33) - 0.87 (0.20) 0.77 (0.23) -
Women Without infection, during the day of completion of the questionnaire
N 102 96 98 99 95 490
(UK TTO formula) 0.73 (0.25) 0.68 (0.34) 0.60 (0.31) 0.75 (0.24) 0.69 (0.34) 0.69 (0.30)
(country specific formula) Mean (Sd) 0.78 (0.22) 0.73 (0.33) - 0.87 (0.20) 0.77 (0.23) -
General population (b)
N 3395 2892 5473 4709 3552 4000 -
Mean (Sd) 0.92 (0.22) 0.89 (−) 0.93 (−) 0.90 (−) 0.94 (−) 0.88 (−) 0.91 (−)
Adjusted mean (Sd) - 0.86 (−) 0.89 (−) 0.87 (−) 0.92 (−) - -
Source Dennis
et al.
König et al. König et al. König et al. König et al. Kind et al. -
Difference (a - b)
(UK TTO formula) Mean (Sd) −0.18 (−) −0.17 (−) −0.26 (−) −0.29 (−) −0.18 (−) −0.20 (−) −0.21 (−)
Adjusted mean (Sd) - −0.14 (−) −0.22 (−) −0.26 (−) −0.16 (−) - -
(country specific formula) Mean (Sd) −0.18 (−) −0.12 (−) −0.21 (−) - −0.08 (−) −0.12 (−) -
Mean (Sd)
(adjusted)
- −0.09 (−) −0.17 (−) - −0.06 (−) - -
During the last acute episode (at the completion of the questionnaire or before) (c)*
N 100 107 100 105 106 102 520
(UK TTO formula) Mean (Sd) 0.71 (0.27) 0.52 (0.33) 0.48 (0.34) 0.42 (0.35) 0.62 (0.28) 0.51 (0.36) 0.51 (0.34)
(country specific formula) Mean (Sd) 0.71 (0.27) 0.59 (0.31) 0.54 (0.35) - 0.76 (0.24) 0.64 (0.24) -
Symptom-free period (at the completion of the questionnaire or before) (d)*
N 100 107 100 105 106 102 520
(UK TTO formula) Mean (Sd) 0.86 (0.24) 0.72 (0.26) 0.68 (0.34) 0.62 (0.31) 0.77 (0.24) 0.69 (0.33) 0.70 (0.30)
(country specific formula) Mean (Sd) 0.86 (0.24) 0.77 (0.23) 0.73 (0.32) - 0.87 (0.19) 0.77 (0.23) -
Difference (c - d)*
N 100 107 100 105 106 102 520
Utility score (UK TTO formula) Mean (Sd) −0.15 (0.23) −0.20
(0.29)
−0.20
(0.34)
−0.20
(0.30)
−0.15
(0.23)
−0.18
(0.27)
−0.19
(0.29)
Utility score (country specific
formula)
Mean (Sd) −0.15 (0.23) −0.19
(0.25)
−0.19
(0.32)
- −0.12
(0.20)
−0.12
(0.18)
-
*Total do not include data from the UK, as questions about symptoms were formulated differently in the UK version.
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year) was estimated at around 33 hours per year. The
costs of lost productivity over 12 months were estimated
at €1,130/per year for France, €852/per year for the UK
(i.e. £713) and €974/per year for US (i.e. $1,261).
Correlations between instruments
Correlations between SF-36 summary scales and EQ-5D
ratings by dimension were weak to moderate. The SF-36
mental component summarily was moderately correlated
with the EQ-5D anxiety/depression dimension (Spearman’s
correlation: 0.45), and weakly correlated with other dimen-
sions (0.18 to 0.23). On the opposite, the SF-36 physical
component summary was moderately correlated with mo-
bility, self-care, usual activities and pain/discomfort (0.37
to 0.42), and weakly with anxiety/depression (0.21).
The number of missing hours was strongly associated
with the EQ-5D, specifically with ratings of problems
with usual activities.
Discussion
The main objective of the survey was to elicit utility
values for RVVC. The EQ-5D questionnaire, a widely
used and recommended generic questionnaire for utility
value elicitation, was used to quantify the impact of
RVVC. This also allowed for comparison with general
population norms and other diseases. The SF-36, an-
other generic questionnaire, was used to describe in
more detail the impact of RVVC in HRQoL.
The average health state utility for women with RVVC
was estimated at 0.70 (based on the UK TTO formula),
despite the use of long term antifungal therapy in 85% of
participants. According to US and UK catalogues of util-
ities, this situates RVVC as worse than headache/migraine
for example, and similar to asthma or COPD [34,35]. The
difference vs. age-adjusted population norms was esti-
mated at −0.21 globally, based on the UK tariff, and
ranged from −0.12 for France to −0.21 for Spain, using
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Figure 2 SF-36 T-scores for each dimension. All scales in the general population have the same average (50) and the same standard deviation (10).
Table 5 Multivariate regression on the EQ-5D utility today (except UK)
Category Reference Estimates P-value
Age (years) −0.0021 0.0779
The last time you experienced symptoms 1 to 4 weeks ago This week 0.1161 0.0004
1 to 3 months 0.1507 0.0001
More than 3 months 0.1633 0.0033
Number of yeast infection 4-5 infections 6 infections and more 0.0507 0.0762
When did you stop the antifungal long-term therapy? In the past 12 months This treatment is still ongoing 0.1566 0.0002
More than 12 months ago 0.2249 0.0001
Never treated 0.2081 <.0001
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tariffs reflecting local preference weights. A minimal clin-
ically important difference of 0.074 has been reported in
the literature [36]. Thus, the utility decrement among
women with RVVC was found to be clinically important
for all countries.
SF-36 dimensions were all affected among women
with RVVC in general. The greatest impact of the dis-
ease was found on the emotional domains compared to
the general population, but significant differences were
found for other domains as well. The summary scores of
the SF-36 also suggested that mental health was strongly
affected by RVVC (mean score: 34.72; 95% CI: [33.74;
35.71] for all countries), which was consistent with the
results from EQ-5D. This outcome was consistent with
findings by Mendling et al., who also reported a stronger
impact on mental health than on physical health using
SF-36, albeit to a somewhat lesser extent [18].
Acute RVVC episodes impacted subjective health sta-
tus negatively, but elicited health status was also affected
outside RVVC episodes notably due to a large impact of
the disease on anxiety or depression that lasts over time.
Stress and a substantial psychological burden that is as-
sociated with the disease, up to depression, has been de-
scribed previously and confirms the findings of the
present study [17,37,38]. It is however not clear to what
extent stress, anxiety and depression are causes or symp-
toms of RVVC, or both in an amplifying loop.
The impact of RVVC on subjective health status and
HRQoL exists in spite of existing treatments, such as
short- or long-term antifungal therapy. Many participants
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Figure 3 Proportion of women with some/severe problems during the last acute infection/outside infection.
Table 6 Productivity lost
UK France Spain Italy Germany USA Source
100 107 100 105 106 102
Number of employed women 71 (71.0%) 83 (77.5%) 62 (62.0%) 60 (57.1%) 78 (73.5%) 69 (67.7%)
Missing hours from work/RVVC episode 5.86 (12.39) 8.72 (17.67) 3.37 (9.62) 5.23 (8.29) 6.12 (10.59) 7.00 (10.80)
Number of missing hours/year 33.6 45.5 17.6 27.6 30.9 39.2
Average annual hours actually worked per worker - 2011 (b) 1625 1476 1690 1774 1413 1787 OECD
Average annual wages (National Currency Unit) - 2011 (c) 31413 34284 27010 28109 33766 54450 OECD
Average daily wages (National Currency Unit) - 2011 (d) = (c)/(b) 19.33 23.23 15.98 15.84 23.9 30.47
Average daily wages. in € 19.33* 23.23 15.98 15.84 23.9 23.53**
Monetary equivalence of the annual productivity loss (€)
(mean.sd)
851.6
(1580)
1129.9
(2316)
265.7
(677)
455.1
(679)
785.0
(1384)
973.9
(1613)
*Conversion rate: 31/12/2011: 1.193.
**Conversion rate: 31/12/2011: 0.7722.
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had previously received long-term antifungal therapy.
Women who were receiving a long-term antifungal ther-
apy at the time of the study had worse subjective health
status compared to others; this was likely related to the
fact that those who sought treatment were the women in
whom subjective health status was most affected.
The impact on productivity, estimated at 33 work hours
lost per year on average, was high. Associated costs ranged
from €266/year for Spain to €1,130/year for France. These
values were higher than expected, but they seemed cred-
ible as there was good internal consistency between the
rating of usual activities and the number of missed work
hours per episode from WPAI.
The survey was conducted in a large sample of women
(n = 620), covering six countries. Despite variability in
health state utility values and HRQoL scores between
countries, the key findings were consistent between coun-
tries. Differences in utility values and HRQoL scores be-
tween RVVC and the general population were always
significant and clinically important. In addition, the corre-
lations between EQ-5D and SF-36 were in line with expec-
tations: the EQ-5D physical dimensions were mostly
correlated to SF-36 physical domains and the EQ-5D anx-
iety/disorder rating was mostly correlated to SF-36 mental
domains. The extent of correlation between EQ-5D and
SF-36 was consistent with previous studies, also reporting
low to moderate correlations between the two instruments
(for example in low back pain [39]).
A limitation of this study was that data on co-morbidities
was not available. It is possible that the difference in
utility between women with RVVC and the general
population was partially attributable to co-morbidities
with higher occurrence in RVVC patients than in the gen-
eral population [1,2]. In some rare cases, yeast infection
may be an early sign of diabetes [40]. This could explain
why there were more women with RVVC reporting prob-
lems on dimensions such as mobility, outside infection pe-
riods. However, regression analysis demonstrated that
utility worsens with increasing disease severity, and there-
fore, that the estimated reduction in utility was at least
partially attributable to RVVC itself. In addition, vestibular
vulvodynia, is often present in RVVC patients. The causal
relationship between RVVC and vestibular vulvodynia is
not clear. Vestibular vulvodynia could be a symptom of
RVVC or a comorbidity triggered by RVVC as suggested
by a recent report [41], although this pain syndrome may
also have other origins.
The study was also limited by the fact that online self-
reported answers could not be verified, in particular the
diagnosis. However, women were not asked to state dir-
ectly, whether they had RVVC or not. The screening sec-
tion was designed in a way that respondents did not know
that the topic was RVVC until the completion of all
five screening questions, where they were asked about
a physician-diagnosed episode of VVC (or suggested
synonyms) and the number of such episodes over the past
12 months. Although women could receive a small
financial incentive to participate, (from €0.5 to €5), this in-
centive was sufficiently small not to attract “false respon-
dents”, who would participate only in order to receive the
financial incentive.
The proportion of women with symptoms on the day
of the questionnaire (5.8%) was lower than expected
(according to average number of days and average dur-
ation of an episode). Potential reasons for this relatively
low proportion may be that symptoms are not continuous
during acute episodes, or that women with RVVC are less
likely to participate in online surveys during acute epi-
sodes. However, the sum of the number of women with an
acute episode at the time of questionnaire completion or
in the past week was consistent with the number of epi-
sodes per year and the duration of an acute episode.
A minor limitation for the UK sample was that the ques-
tion about the presence of symptoms on the day of com-
pleting the questionnaire appeared to be misunderstood in
the soft launch and therefore had to be rephrased before
launching the surveys in other countries. Utilities for acute
episodes and periods in between episodes could thus not
be separated for the UK. However all other parts of the
questionnaire were identical, and global RVVC utilities on
the day of questionnaire completion are comparable be-
tween the UK and other countries.
When testing for the significance between utilities
among women with RVVC and the general population,
the standard error around utility norms was ignored.
Standard errors around the utility norms were not avail-
able for some countries, but these were known to be small
compared to estimated differences between women with
RVVC and women in general for the UK and the US. In
the UK, the standard error around the utility norm for
women were 0.005 (SD = 0.22; N = 1,925). In the US,
standard errors of scores in each age or gender category
were around 0.02.
Another limitation was the calculation of the utility
during acute episodes by pooling women having an
acute episode at completion of the questionnaire with
women recalling the last acute episode (having occurred
on average 2.2 months ago, but in any case within the
past 12 months). It was uncertain how well women
could recall the quality of life during the last episode.
We noted, however, that the reported difference in EQ-
5D utility during and between episodes was very similar
for patients who answered the questionnaire during an
acute episode and those who answered in the interval
between episodes (0.20 and 0.19, respectively).
We used modified versions of the WPAI questionnaire.
Questions were reworded replacing “During the past
seven days …” by “Thinking back to your most recent
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yeast infection…” and the “…your health problems…” by
“…your last infection…”. The WPAI questionnaire, while
being validated in English and Spanish, has not been vali-
dated in German, French or Italian placing a potential
limitation on the accuracy of the data gathered from re-
spondents from these countries. However, all translations
were carefully reviewed by native speakers and clinicians.
Conclusions
This survey showed that subjective health status and
HRQoL are substantially diminished during acute epi-
sodes, but also outside these episodes in women with
RVVC, including some women who have received long-
term antifungal therapy as recommended by guidelines.
It appears that many women with RVVC suffered some
discomfort, and most importantly anxiety between acute
episodes. The survey also revealed that the disease has a
strong impact on patient’s usual daily activities and
work. RVVC was found to be associated with significant
productivity costs. These findings highlight the need for
more effective ways to manage RVVC.
Endnotes
aThe proportion of women reporting having symptoms
while answering the questionnaire (80%) was much
higher than expected in the UK. The question was prob-
ably misunderstood. Based on the UK results, the ques-
tions on symptoms were revised before the launch in
other countries.
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